Table 6.
Epidemiological, clinical and serological data of MS patients before DMT onset according to the genetic background associated with EBNA-1 IgG titers.
| EPIDEMIOLOGICAL AND CLINICAL DATA | ||||||
|---|---|---|---|---|---|---|
| n | Gender (F/M) | Age | Starting Age | MSSS | ARR | |
| DR3+/DR6-/rs11129295TT- | 40 | 26/14 | 36 | 31.5 | 2.98 | 1.1 |
| Rest of MS patients | 247 | 168/79 | 36 | 28.0 | 3.34 | 1.0 |
| p value* | n.s. | n.s. | 0.006 | n.s. | n.s. | |
| SEROLOGICAL DATA | ||||||
| n | EBNA-1 IgG titers (AU) | EBNA-1 IgG % pos. (n/N) | VCA IgG titers (AU) | VCA IgG % pos. (n/N) | ||
| DR3+/DR6-/rs11129295TT- | 40 | 24.7 | 95.0% (38/40) | 56.5 | 100% (40/40) | |
| Rest of MS patients | 247 | 25.4 | 98.8% (244/247) | 60.2 | 99.6% (246/247) | |
| p value* | 0.009 | n.s. | n.s. | n.s. | ||
*Student t test (for continuous variables) and Chi-square test (for categorical variables). Median values for continuous variables. n.s., not significant; MSSS, Multiple sclerosis severity score (before DMT onset). ARR, annualized relapse rate (since the beginning of the disease until DMT onset); AU, arbitrary units; % pos., percentage of positive samples. Bold values indicates the statistically significant values.